AR072281A1 - Isoquinolinas e isoquinolinonas sustituidas - Google Patents
Isoquinolinas e isoquinolinonas sustituidasInfo
- Publication number
- AR072281A1 AR072281A1 ARP090102285A ARP090102285A AR072281A1 AR 072281 A1 AR072281 A1 AR 072281A1 AR P090102285 A ARP090102285 A AR P090102285A AR P090102285 A ARP090102285 A AR P090102285A AR 072281 A1 AR072281 A1 AR 072281A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkylene
- aryl
- cycloalkyl
- heterocycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Estos compuestos son utiles para el tratamiento y/o prevencion de enfermedades asociadas con la Rho-quinasa y/o la fosforilacion mediada por la Rho-quinasa de la fosfatasa de miosina de cadena ligera, y a composiciones que contienen dichos compuestos. Reivindicacion 1: Un compuesto de la formula (1) en la que R1 es H, OH o NH2; R3 es H, halogeno, CN, alquilo C1-6, OH, NH2 o NHR'; R4 es H, halogeno, hidroxi, CN, alquilo C1-6, R' o alquileno C1-6-R'; R5 es H, halogeno, CN, alquilo C1-6, o R'; R7 es H, halogeno, CN, alquilo C1-6, O-alquilo C1-6, R' o SO2-NH2; R8 es H, halogeno o alquilo C1-6; R9 es R', OH, halogeno, alquilo C1-6, O-alquilo C1-6, alquileno C1-6-R', alquenilo C2-6, alquinilo C2-6, alquileno C1-6-O-R', alquileno C1-6-CH[R']2, alquileno C1-6-C(O)-R', alquileno C1-6-C(O)NH2, alquileno C1-6-C(O)NH-R', alquileno C1-6-C(O)NH-alquilo C1-6, alquileno C1-6-C(O)N[alquilo C1-6]2, alquileno C1-6-C(O)N[R']2, alquileno C1-6-C(O)O-alquilo C1-6, COOH, C(O)O-alquilo C1-6, C(O)OR', C(O)-alquilo C1-6, C(O)R', CONH2, C(O)-NH-alquenilo C2-6, C(O)-NH-alquinilo C2-6, C(O)NH-alquilo C1-6, C(O)NHR', C(O)-NH-alquileno C1-6-R', C(O)N[alquilo C1-6]R', C(O)N[alquilo C1-6]2, C(O)-alquileno C1-6-R', o C(O)O-alquileno C1-6-R'; R6 está ausente o es un alquileno C1-4 unido al anillo de cicloalquilo, donde el alquileno C1-4 forma un segundo enlace con un átomo de carbono diferente del anillo de cicloalquilo para formar un sistema de anillos bicíclicos, donde en el sistema de anillos bicíclicos opcionalmente uno o dos átomos de carbono se reemplazan por un grupo seleccionado independientemente entre O, N-R15, S, SO o SO2 o, si m y s son 2, m es 3 y s es 1, o m es 4 y s es 0, R6 es CH2-CH-(CH2)2, que se une con un CH2 al anillo de cicloalquilo y los otros dos CH2 se unen a átomos de carbono diferentes del anillo de cicloalquilo, y, si m es 3 y s es 3, R6 son dos grupos metileno unidos a átomos de carbono diferentes del anillo de cicloalquilo, donde los grupos metileno o el grupo CH2-CH-(CH2)2 se unen a átomos de carbono del anillo de cicloalquilo de tal manera que forman un sistema de adamantano de la formula (2) en la que L puede unirse a cualquier átomo de carbono secundario o terciario, y en la que el sistema de anillos bicíclicos o el sistema de adamantano está sin sustituir u opcionalmente sustituido por R9; R10 es H arilo C6-10, arilo C6-10, O-alquileno C1-6-arilo C6-10, o heteroarilo C5-10, donde el arilo C6-10 o el heteroarilo C5-10 está sin sustituir o sustituido; R11 es H, alquilo C1-6, alquileno C1-6-R'; cicloalquilo C3-8, heteroarilo C5-10, heterocicloalquilo C3-8, arilo C6-10, o R11 y R12, junto con el átomo de C al que están unidos, forman un anillo cicloalquilo C3-8 o heterocicloalquilo C3-8; R12 es alquilo C1-6, cicloalquilo C3-8, heteroarilo C5-10, heterocicloalquilo C3-8, o arilo C6-10; o R12 es H, con la condicion de que r =2 y el otro R12 no sea H; o R11 y R12, junto con el átomo de C al que están unidos, forman un anillo cicloalquilo C3-8 o heterocicloalquilo C3-8; R13 y R14 son independientemente entre sí H, R', alquilo C1-6; alquileno C1-6-R', alquileno C1-6-O-alquilo C1-6, alquileno C1-6-O-R', alquileno C1-6-CH[R']2, alquileno C1-6-C(O)-R', alquileno C1-6-C(O)NH2, alquileno C1-6-C(O)NH-R', alquileno C1-6-C(O)NH-alquilo C1-6, alquileno C1-6-C(O)N[alquilo C1-6]2, alquileno C1-6-C(O)N[R']2, alquileno C1-6-C(O)O-alquilo C1-6, C(O)O-alquilo C1-6, C(O)OR', C(O)-alquilo C1-6, C(O)R', C(O)NH-alquilo C1-6, C(O)NHR', C(O)N[alquil C1-6]R', C(O)N[alquilo C1-6]2, C(O)-alquileno C1-6-R', C(O)O-alquileno C1-6-R'; o R13 y R14, junto con el átomo de N al que están unidos, forman un heterocicloalquilo C3-8; R15 es H o alquilo C1-6; n es 0, 1, 2, 3 o 4; m es 1, 2, 3 o 4; s es 0, 1, 2 o 3; r es 1 o 2; L es O(CH2)p, S(CH2)p, S(O)(CH2)p, SO2(CH2)p, NH(CH2)p, N-alquil C1-6-(CH2)p, N-cicloalquil C3-6-(CH2)p; o N[alquileno C1-3-R']-(CH2)p; p es 0, 1, 2, 3 o 4; R' es cicloalquilo C3-8, heteroarilo C5-10, heterocicloalquilo C3-8, arilo C6-10; donde en los restos R3 a R15, el alquilo o alquileno está sin sustituir u opcionalmente sustituido una o más veces con OH, OCH3, C(O)OH, C(O)OCH3, NH2, NHCH3, N(CH3)2, C(O)NH2, C(O)NHCH3 o C(O)N(CH3)2; donde en los restos R3 a R15 el cicloalquilo o heterocicloalquilo está sin sustituir u opcionalmente sustituido una o más veces con alquilo C1-6, halogeno, OH, OCH3, C(O)OH, C(O)OCH3, NH2, NHCH3, N(CH3)2, C(O)NH2, C(O)NHCH3 o C(O)N(CH3)2, donde en los restos R3 a R15 el alquilo o alquileno está sin sustituir u opcionalmente sustituido una o más veces con halogeno; donde en los restos R3 a R15 el arilo C6-10 y el heteroarilo C5-10 están sin sustituir u opcionalmente sustituidos, una o más veces, por un grupo seleccionado independientemente entre halogeno, OH, NO2, N3, CN, C(O)-alquilo C1-6, C(O)-arilo C6-10, COOH, COO-alquilo C1-6, C(O)NH2, C(O)NH-alquilo C1-6, C(O)N[alquilo C1-6]2, cicloalquilo C3-8, alquilo C1-6, alquileno C1-6-NH-alquilo C1-6, alquileno C1-6-N[alquilo C1-6]2, alquenilo C2-6, alquinilo C2-6, O-alquilo C1-6, O-C(O)-alquilo C1-6, PO3H2, SO3H, SO2-NH2, SO2NH-alquilo C1-6, SO2-N[alquilo C1-6]2, S-alquilo C1-6; SO-alquilo C1-6, SO2-alquilo C1-6, SO2-N=CH-N[alquilo C1-6]2, SF5, C(NH)(NH2), NH2, NH-alquilo C1-6, N[alquilo C1-6]2, NH-C(O)-alquilo C1-6, NH-C(O)O-alquilo C1-6, NH-SO2-alquilo C1-6, NH-SO2-arilo C6-10, NH-SO2-heteroarilo C5-10, NH-SO2-heterocicloalquilo C3-8, N-alquil C1-6-C(O)-alquilo C1-6, N-alquil C1-6-C(O)O-alquilo C1-6, N-alquil C1-6-C(O)-NH-alquilo C1-6, arilo C6-10, alquileno C1-6-arilo C6-10, O-arilo C6-10, O-alquileno C1-6-arilo C6-10, heteroarilo C5-10, heterocicloalquilo C3-8, alquileno C1-6-heteroarilo C5-10, alquileno C1-6-heterocicloalquilo C3-8, O-alquileno C1-6-heteroarilo C5-10, O-alquileno C1-6-heterocicloalquilo C3-8, donde dicho arilo C6-10, heteroarilo C5-10, heterocicloalquilo C3-8 o cicloalquilo C3-8 puede estar sustituido, de una a tres veces, con un grupo, seleccionado independientemente entre halogeno, OH, NO2, CN, O-alquilo C1-6, alquilo C1-6, NH2, NH-alquilo C1-6, N[alquilo C1-6]2, SO2CH3, COOH, C(O)O-alquilo C1-6, CONH2, alquileno C1-6-O-alquilo C1-6, alquileno C1-6-O-arilo C6-10 u O-alquileno C1-6-arilo C6-10; o donde el grupo arilo C6-10 está sustituido vecinalmente con un grupo O-alquileno C1-4-O, por lo que se forma, junto con los átomos de carbono a los que están unidos los átomos de oxígeno, un anillo de 5-8 miembros; y donde los sustituyentes arilo de los grupos arilo C6-10, heteroarilo C5-10, heterocicloalquilo C3-8 o cicloalquilo C3-8 pueden no estar más sustituidos adicionalmente con un grupo que contiene arilo, heteroarilo, heterocicloalquilo o cicloalquilo C3-8; sus formas estereoisoméricas y/o tautoméricas y/o sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08290606 | 2008-06-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR072281A1 true AR072281A1 (es) | 2010-08-18 |
Family
ID=40049863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090102285A AR072281A1 (es) | 2008-06-24 | 2009-06-22 | Isoquinolinas e isoquinolinonas sustituidas |
Country Status (33)
Country | Link |
---|---|
US (1) | US8541449B2 (es) |
EP (1) | EP2303846B1 (es) |
JP (1) | JP5713893B2 (es) |
KR (1) | KR101638326B1 (es) |
CN (1) | CN102131784B (es) |
AR (1) | AR072281A1 (es) |
AU (1) | AU2009262517B2 (es) |
BR (1) | BRPI0914696A2 (es) |
CA (1) | CA2728137C (es) |
CO (1) | CO6321250A2 (es) |
CR (1) | CR11831A (es) |
DK (1) | DK2303846T3 (es) |
DO (1) | DOP2010000394A (es) |
EC (1) | ECSP10010705A (es) |
ES (1) | ES2541827T3 (es) |
HK (1) | HK1158644A1 (es) |
HR (1) | HRP20150726T1 (es) |
HU (1) | HUE026617T2 (es) |
IL (1) | IL210113A (es) |
MA (1) | MA32400B1 (es) |
MX (1) | MX2010013975A (es) |
MY (1) | MY157330A (es) |
NZ (1) | NZ590070A (es) |
PE (1) | PE20110059A1 (es) |
PL (1) | PL2303846T3 (es) |
PT (1) | PT2303846E (es) |
RU (1) | RU2538588C2 (es) |
SI (1) | SI2303846T1 (es) |
SV (1) | SV2010003772A (es) |
TW (1) | TWI462907B (es) |
UY (1) | UY31925A (es) |
WO (1) | WO2009156100A1 (es) |
ZA (1) | ZA201008119B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010013974A (es) * | 2008-06-24 | 2011-01-14 | Sanofi Aventis | Isoquinolinas e isoquinolinonas 6-sustituidas. |
EP2733141B1 (en) | 2011-07-15 | 2019-01-09 | Shionogi & Co., Ltd. | Azabenzimidazole derivative having ampk-activating activity |
WO2013113773A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113776A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
JP2015508752A (ja) | 2012-02-03 | 2015-03-23 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 殺菌性ピリミジン化合物 |
WO2013113788A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113720A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
WO2013113716A1 (en) | 2012-02-03 | 2013-08-08 | Basf Se | Fungicidal pyrimidine compounds |
IN2014DN07220A (es) | 2012-02-03 | 2015-04-24 | Basf Se | |
US9738642B2 (en) | 2013-09-19 | 2017-08-22 | Bristol-Myers Squibb Company | Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders |
FR3017868A1 (fr) | 2014-02-21 | 2015-08-28 | Servier Lab | Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP3294871A1 (en) | 2015-05-12 | 2018-03-21 | Platod | Combination of pharmacological and microfluidic features for improved platelets production |
JP6906105B2 (ja) * | 2017-06-16 | 2021-07-21 | 成都先導薬物開発股▲ふん▼有限公司Hitgen Ltd. | Rockを阻害する化合物及びその使用 |
CN109810174B (zh) * | 2017-11-21 | 2021-01-01 | 首都医科大学 | 异喹啉-3-甲酰-TARGD(aa)aa,其制备,抗静脉血栓活性和应用 |
CN110317169B (zh) * | 2018-03-29 | 2022-06-03 | 复旦大学 | 一种1-取代异喹啉酮化合物及其制备方法 |
WO2023076812A1 (en) | 2021-10-30 | 2023-05-04 | Aneuryst, Inc. | Treatments for disturbed cerebral homeostasis |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2702600A1 (de) * | 1977-01-22 | 1978-07-27 | Thomae Gmbh Dr K | Neue aminoalkoxyphenyl-derivate |
FR2485537B2 (fr) | 1977-04-13 | 1986-05-16 | Anvar | Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant |
EP0541559A1 (en) | 1990-07-31 | 1993-05-19 | E.I. Du Pont De Nemours And Company | Catalytic equilibration of selected halocarbons |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
GB9516709D0 (en) | 1995-08-15 | 1995-10-18 | Zeneca Ltd | Medicament |
ZA9610741B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
SI0956865T2 (sl) | 1996-08-12 | 2011-04-29 | Mitsubishi Pharma Corp | Zdravila, ki obsegajo inhibitor Rho-kinaze |
JPH1087629A (ja) | 1996-09-18 | 1998-04-07 | Fujisawa Pharmaceut Co Ltd | 新規イソキノリン誘導体、およびその医薬用途 |
EP1007525A1 (en) | 1997-08-29 | 2000-06-14 | Zeneca Limited | Aminometyl oxooxazolidinyl benzene derivatives |
TW575567B (en) * | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
GB9912701D0 (en) | 1999-06-01 | 1999-08-04 | Smithkline Beecham Plc | Novel compounds |
US6541456B1 (en) | 1999-12-01 | 2003-04-01 | Isis Pharmaceuticals, Inc. | Antimicrobial 2-deoxystreptamine compounds |
MXPA02007036A (es) | 2000-01-20 | 2002-12-13 | Eisai Co Ltd | Compuesto de piperidina novedoso y composicion farmaceutica del mismo. |
US7217722B2 (en) | 2000-02-01 | 2007-05-15 | Kirin Beer Kabushiki Kaisha | Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same |
AU2001239947A1 (en) | 2000-02-29 | 2001-09-12 | Curis, Inc. | Methods and compositions for regulating adipocytes |
GB0004887D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
AU2001296008A1 (en) | 2000-10-27 | 2002-05-06 | Takeda Chemical Industries Ltd. | Process for preparing substituted aromatic compounds and intermediates therefor |
WO2002055496A1 (en) | 2001-01-15 | 2002-07-18 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
SE0101038D0 (sv) | 2001-03-23 | 2001-03-23 | Astrazeneca Ab | Novel compounds |
WO2002088101A2 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
JPWO2002100833A1 (ja) | 2001-06-12 | 2004-09-24 | 住友製薬株式会社 | Rhoキナーゼ阻害剤 |
GB0117899D0 (en) | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
ATE447955T1 (de) | 2001-08-24 | 2009-11-15 | Univ Yale | Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel |
WO2003024450A1 (en) | 2001-09-20 | 2003-03-27 | Eisai Co., Ltd. | Methods for treating prion diseases |
SE0104340D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New compounds |
JPWO2004009555A1 (ja) * | 2002-07-22 | 2005-11-17 | 旭化成ファーマ株式会社 | 5−置換イソキノリン誘導体 |
JPWO2004024717A1 (ja) | 2002-09-12 | 2006-01-05 | 麒麟麦酒株式会社 | キナーゼ阻害活性を有するイソキノリン誘導体およびそれを含む医薬 |
US20050014783A1 (en) | 2003-05-29 | 2005-01-20 | Schering Aktiengesellschaft | Use of Rho-kinase inhibitors in the treatment of aneurysm and cardiac hypertrophy |
US20070021404A1 (en) | 2003-06-24 | 2007-01-25 | Dan Peters | Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
US7691879B2 (en) | 2003-09-23 | 2010-04-06 | Merck Sharp & Dohme Corp. | Isoquinoline potassium channel inhibitors |
CN1856476A (zh) | 2003-09-23 | 2006-11-01 | 默克公司 | 异喹啉酮钾通道抑制剂 |
US20050067037A1 (en) | 2003-09-30 | 2005-03-31 | Conocophillips Company | Collapse resistant composite riser |
EP1671962A1 (en) | 2003-10-10 | 2006-06-21 | Ono Pharmaceutical Co., Ltd. | Novel fused heterocyclic compound and use thereof |
JP2007008816A (ja) * | 2003-10-15 | 2007-01-18 | Ube Ind Ltd | 新規イソキノリン誘導体 |
EP1689719A1 (en) | 2003-11-25 | 2006-08-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
EP1729761A4 (en) | 2004-03-05 | 2008-09-03 | Eisai Co Ltd | TREATMENT OF CADASIL WITH CHOLINESTERASE INHIBITORS |
SE0400850D0 (sv) | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
US7517991B2 (en) | 2004-10-12 | 2009-04-14 | Bristol-Myers Squibb Company | N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
PT1899322E (pt) | 2005-06-28 | 2009-11-09 | Sanofi Aventis | Derivados de isoquinolina como inibidores de rho-cinase |
NI200800025A (es) | 2005-07-26 | 2009-03-03 | Derivados de isoquinolona sustituidos con piperidinilo en calidad de inhibidores de rho-quinasa | |
ATE521595T1 (de) * | 2005-07-26 | 2011-09-15 | Sanofi Sa | Cyclohexylaminisochinolonderivate als rho-kinase- inhibitor |
TW200745101A (en) | 2005-09-30 | 2007-12-16 | Organon Nv | 9-Azabicyclo[3.3.1]nonane derivatives |
US7618985B2 (en) | 2005-12-08 | 2009-11-17 | N.V. Organon | Isoquinoline derivatives |
TW200738682A (en) | 2005-12-08 | 2007-10-16 | Organon Nv | Isoquinoline derivatives |
US7893088B2 (en) | 2006-08-18 | 2011-02-22 | N.V. Organon | 6-substituted isoquinoline derivatives |
AU2007338408B2 (en) | 2006-12-27 | 2012-07-26 | Sanofi-Aventis | Substituted isoquinoline and isoquinolinone derivatives |
CA2673920C (en) | 2006-12-27 | 2015-03-24 | Sanofi-Aventis | Cycloalkylamine substituted isoquinoline derivatives |
JP5405314B2 (ja) | 2006-12-27 | 2014-02-05 | サノフイ | シクロアルキルアミン置換イソキノロン誘導体 |
AU2007338409B2 (en) | 2006-12-27 | 2012-12-13 | Sanofi-Aventis | Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives |
SI2102164T1 (sl) | 2006-12-27 | 2011-03-31 | Sanofi Aventis | Izokinolinski in izokinolinonski derivati, substituirani s cikloalkilaminom |
MX2009005825A (es) | 2006-12-27 | 2009-06-16 | Sanofi Aventis | Derivados de isoquinolina e isoquinolinona sustituidos en calidad de inhibidores de rho-quinasa. |
CN101573354B (zh) | 2006-12-27 | 2014-02-12 | 塞诺菲-安万特股份有限公司 | 取代的异喹啉类及其作为Rho-激酶抑制剂的用途 |
-
2009
- 2009-06-19 RU RU2011102456/04A patent/RU2538588C2/ru not_active IP Right Cessation
- 2009-06-19 PE PE2010001193A patent/PE20110059A1/es not_active Application Discontinuation
- 2009-06-19 MX MX2010013975A patent/MX2010013975A/es active IP Right Grant
- 2009-06-19 JP JP2011515175A patent/JP5713893B2/ja not_active Expired - Fee Related
- 2009-06-19 WO PCT/EP2009/004421 patent/WO2009156100A1/en active Application Filing
- 2009-06-19 AU AU2009262517A patent/AU2009262517B2/en not_active Ceased
- 2009-06-19 CA CA2728137A patent/CA2728137C/en not_active Expired - Fee Related
- 2009-06-19 CN CN200980132930.XA patent/CN102131784B/zh not_active Expired - Fee Related
- 2009-06-19 BR BRPI0914696A patent/BRPI0914696A2/pt not_active IP Right Cessation
- 2009-06-19 DK DK09768949.1T patent/DK2303846T3/en active
- 2009-06-19 EP EP20090768949 patent/EP2303846B1/en active Active
- 2009-06-19 NZ NZ590070A patent/NZ590070A/en not_active IP Right Cessation
- 2009-06-19 HU HUE09768949A patent/HUE026617T2/en unknown
- 2009-06-19 PT PT97689491T patent/PT2303846E/pt unknown
- 2009-06-19 SI SI200931226T patent/SI2303846T1/sl unknown
- 2009-06-19 US US13/000,754 patent/US8541449B2/en not_active Expired - Fee Related
- 2009-06-19 KR KR1020107028887A patent/KR101638326B1/ko active IP Right Grant
- 2009-06-19 PL PL09768949T patent/PL2303846T3/pl unknown
- 2009-06-19 ES ES09768949.1T patent/ES2541827T3/es active Active
- 2009-06-19 MY MYPI2010005570A patent/MY157330A/en unknown
- 2009-06-22 UY UY0001031925A patent/UY31925A/es not_active Application Discontinuation
- 2009-06-22 AR ARP090102285A patent/AR072281A1/es unknown
- 2009-06-22 TW TW098120767A patent/TWI462907B/zh not_active IP Right Cessation
-
2010
- 2010-11-12 ZA ZA2010/08119A patent/ZA201008119B/en unknown
- 2010-12-07 CR CR11831A patent/CR11831A/es not_active Application Discontinuation
- 2010-12-17 MA MA33438A patent/MA32400B1/fr unknown
- 2010-12-20 SV SV2010003772A patent/SV2010003772A/es unknown
- 2010-12-20 DO DO2010000394A patent/DOP2010000394A/es unknown
- 2010-12-20 IL IL210113A patent/IL210113A/en not_active IP Right Cessation
- 2010-12-21 CO CO10160331A patent/CO6321250A2/es not_active Application Discontinuation
- 2010-12-22 EC EC2010010705A patent/ECSP10010705A/es unknown
-
2011
- 2011-12-05 HK HK11113109.8A patent/HK1158644A1/xx not_active IP Right Cessation
-
2015
- 2015-07-03 HR HRP20150726TT patent/HRP20150726T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR072281A1 (es) | Isoquinolinas e isoquinolinonas sustituidas | |
AR064493A1 (es) | Derivados de isoquinolina e isoquinolinona sustituidos | |
AR064531A1 (es) | Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la rho-quinasa | |
AR064492A1 (es) | Derivados de isoquinolona sustituidos con cicloalquilamina | |
AR064533A1 (es) | Derivados de isoquinolina e isoquinolinona sustituidos y su uso en la produccion de un medicamento para el tratamiento de enfermedades relacionadas con la inhibicion de la rho-quinasa. | |
AR057082A1 (es) | Derivados de ciclohexilaminisoquinolona | |
AR054518A1 (es) | Derivados de isoquinolina | |
AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
AR086538A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE b-AMILOIDE | |
AR082029A1 (es) | Derivados de heterociclos nitrogenados, composiciones y metodos para modular la via de señalizacion de wnt | |
ECSP088638A (es) | Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados | |
AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
AR079553A1 (es) | Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros. | |
UY30603A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion y su aplicacion en terapéutica | |
AR080074A1 (es) | Naftiridinas sustituidas y su uso como medicamentos | |
AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
AR084457A1 (es) | Derivados de biciclo[3,2,1]octilamida | |
DOP2010000046A (es) | Compuestos de biciclolactama sustituida | |
AR058124A1 (es) | Derivados de ftalazinona como inhibidores de parp-1 | |
AR068054A1 (es) | Compuestos de pirrolopirimidina | |
EA200702080A1 (ru) | Полициклическое карбомоилпиридоновое производное, обладающее ингибиторной активностью в отношении интегразы вич | |
AR061647A1 (es) | Inhibidores de cxcr2 y sus composiciones farmaceuticas | |
ECSP12012161A (es) | Compuestos en calidad de antagonistas de Bradiquinina-b1 | |
AR073774A1 (es) | Compuestos antibioticos oxazolidinona triciclicos | |
AR047447A1 (es) | Compuestos derivados de amino alcohol con actividad inhibidora de la renina y su uso en composiciones farmaceuticas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |